Stock image of Parkinson's disease nerve cells. The California Institute for Regenerative Medicine (CIRM) has approved an $8 million award to Aspen Neuroscience to advance an investigational stem cell-derived dopaminergic neuron replacement therapy for Parkinson’s disease (PD). This individualized potential therapy is being explored in a first-in-human Phase 1/2a clinical trial for patients with moderate … Continue reading CIRM Funds Clinical Research for Individualized Stem Cell Treatment for Parkinson’s
Disease Areas
Celebrating Black Joy and Spreading Awareness
The streets of Oakland were alive with vibrant colors, infectious energy, and a powerful sense of community as the 2024 Black Joy Parade took center stage on Sunday, February 25. Black Joy Parade-goers with colorful noisemakers walking down Franklin and 19th St. The Black Joy Parade is a yearly celebration of the Black community and … Continue reading Celebrating Black Joy and Spreading Awareness
Neurona Therapeutics Raises $120M Financing, Cell Therapy Shows Positive Outcomes in CIRM-Funded Trial
Photo Courtesy of Neurona Therapeutics/Curtis Myers Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, recently announced the successful completion of a $120 million financing. Neurona’s financial success is an encouraging sign for the stem cell and gene therapy sector, highlighting partnerships with investors and public organizations … Continue reading Neurona Therapeutics Raises $120M Financing, Cell Therapy Shows Positive Outcomes in CIRM-Funded Trial
CIRM invests $26 million in clinical-stage research, including Phase 2b trial for bipolar depression
Stock image of a dual tone brain by Getty Images South San Francisco, CA, Jan. 29, 2024 - The California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, awarded almost $26 million to fund various clinical research — from treating bipolar depression to advancing a therapy for spinal cord injury. … Continue reading CIRM invests $26 million in clinical-stage research, including Phase 2b trial for bipolar depression
Statement from CIRM on the FDA Approval of Gene Therapies for Sickle Cell Disease
The California Institute for Regenerative Medicine (CIRM) applauds and acknowledges the historic significance of the Food and Drug Administration (FDA) approval of Vertex and CRISPR Therapeutics’ CRISPR-based gene therapy (Casgevy) for sickle cell disease. As the first regulatory authorization of a CRISPR-based gene editing therapy in the world, this brings forth a new era of treatment options … Continue reading Statement from CIRM on the FDA Approval of Gene Therapies for Sickle Cell Disease
CIRM Joins World AIDS Day Campaign, Commits $104 Million for HIV Research
John A. Zaia, MD, of Beckman Research Institute of City of Hope This year marks the 35th commemoration of World AIDS Day, a global event that aims to end human immunodeficiency virus (HIV) related stigma, honor people lost to the disease, and reaffirm the commitment to ensuring HIV is no longer a public health threat. … Continue reading CIRM Joins World AIDS Day Campaign, Commits $104 Million for HIV Research
CIRM approves new plan to invest $110 million into basic research in neuropsychiatric diseases
The California Institute for Regenerative Medicine, the world’s largest institute dedicated to regenerative medicine, announced its approval of a new program called ReMIND at the September Independent Citizens Oversight Committee (ICOC) meeting that will eventually award up to $110 million to advance basic research in neuropsychiatric diseases—one of the largest investments of its kind in … Continue reading CIRM approves new plan to invest $110 million into basic research in neuropsychiatric diseases
CIRM Joins #GoGold Childhood Cancer Awareness Campaign
Photo courtesy of Stanford Medicine September is Childhood Cancer Awareness Month and the California Institute for Regenerative Medicine (CIRM) is joining the campaign to #GoGold to raise awareness about childhood cancers and highlight our commitment to funding childhood cancer research. The Impact of Childhood Cancer Cancer remains the number one cause of death by disease for … Continue reading CIRM Joins #GoGold Childhood Cancer Awareness Campaign
CIRM invests $50 million in clinical research, including trial for vision loss
The California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, today awarded $50.1 million to fund clinical-stage research projects aimed at advancing stem cell and gene therapy treatments for a variety conditions ranging from neurodegenerative diseases and blood cancers to HIV/AIDS. The awards will support six projects in the Agency’s … Continue reading CIRM invests $50 million in clinical research, including trial for vision loss
Novartis acquisition validates CIRM’s impact on cystinosis treatment
Dr. Stephanie Cherqui The future looks brighter for cystinosis patients and their families. As one of 7,000 rare diseases, cystinosis causes an abnormal build-up of the amino acid cystine that can lead to organ failure and premature death. With little to no treatment options, children and young adults primarily affected by the condition often have … Continue reading Novartis acquisition validates CIRM’s impact on cystinosis treatment
The Stem Cellar 